NCT07451613 Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease
| NCT ID | NCT07451613 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Leslie Thompson |
| Condition | Huntington Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 21 participants |
| Start Date | 2026-04-06 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 21 participants in total. It began in 2026-04-06 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease. This study is the first time that hNSC-01 is being tested in people.
Eligibility Criteria
Please note this may not be a complete list of eligibility criteria. Inclusion Criteria: * Have decision-making capacity and be able to provide written informed consent. * Are between 18 to 65 years of age * Have genetically confirmed diagnosis of Huntington's Disease * Able to undergo MRI scans, tolerate neurosurgical procedure, blood draws and lumbar puncture. Exclusion Criteria: * Are pregnant * Test positive for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B at Screening * Have an implanted deep brain stimulation device.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07451613 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Huntington Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07451613 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07451613 currently recruiting?
Yes, NCT07451613 is actively recruiting participants. Contact the research team at alphaclinic@hs.uci.edu for enrollment information.
Where is the NCT07451613 trial being conducted?
This trial is being conducted at Irvine, United States.
Who is sponsoring the NCT07451613 clinical trial?
NCT07451613 is sponsored by Leslie Thompson. The trial plans to enroll 21 participants.